RAS-Pathway Mutation Profiles and Clinical Outcomes Among Patients With Colorectal Cancer
Genetic sequencing identifies a treatable mutation in 3% of colorectal cancers, creating precision treatment opportunities for this subset of patients.
Whole-exome sequencing of 1,243 paired colorectal cancer samples from a multi-institutional NCI-funded cohort characterizes KRAS, NRAS, HRAS, BRAF, and PIK3CA mutations with co-occurrence patterns and ethnic-group comparisons. The 3.1% KRAS G12C prevalence defines a targetable precision oncology opportunity, while negative OS associations after adjustment suggest mutation status alone does not determine survival in this unselected population.
What the study was
- Study design
- Cohort study (whole-exome sequencing)
- Category
- T5: Precision oncology and genomic medicine
- Maturity
- Validated
- Journal
- Cancer Medicine
Why it surfaced
Large multi-ethnic NCI-funded WES dataset providing actionable KRAS G12C prevalence data for CRC precision oncology; co-mutation patterns and ethnic disparities in BRAF V600E are directly relevant to watchlist precision oncology and therapy-selection goals.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.